未名医药(002581) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was ¥82,564,768.50, a decrease of 18.96% compared to ¥101,885,863.74 in the same period last year[8] - Net profit attributable to shareholders was ¥24,391,420.52, a significant increase of 138.83% from a loss of ¥62,820,716.49 in the previous year[8] - The net profit after deducting non-recurring gains and losses was ¥23,401,315.22, up 136.16% from a loss of ¥64,718,477.22 year-on-year[8] - The basic earnings per share for the quarter was ¥0.0370, compared to a loss of ¥0.0952 in the same period last year, reflecting an increase of 138.87%[8] - The total comprehensive income for the current period is ¥23,886,274.03, compared to a comprehensive loss of ¥48,667,600.62 in the previous period[138] - The total profit for the current period is ¥20,801,415.13, compared to a total loss of ¥45,208,781.37 in the previous period[138] - The operating profit for the current period is ¥20,878,564.39, while the previous period recorded an operating loss of ¥44,780,480.76[138] - The company reported a decrease in operating costs, contributing to improved profitability compared to the previous period[138] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,490,694,264.35, representing a 1.87% increase from ¥2,444,963,143.56 at the end of the previous year[8] - The total liabilities of the company were CNY 276,172,702.47, up from CNY 254,327,855.41, indicating an increase of about 8.6%[118] - The company's current assets totaled CNY 751,408,020.96, down from CNY 766,162,645.91 at the end of 2020, representing a decrease of approximately 1.1%[112] - The company's long-term equity investments increased to CNY 805,871,312.03 from CNY 751,212,319.95, marking an increase of approximately 7.3%[115] - The total equity attributable to shareholders was CNY 3,511,670,531.72, a slight decrease from CNY 3,513,960,338.32[128] Cash Flow - The net cash flow from operating activities was negative at -¥31,347,735.82, a decline of 147.09% compared to -¥12,686,936.93 in the same period last year[8] - Cash received from operating activities is ¥94,360,938.58, down from ¥102,612,409.13 in the previous period[146] - The company reported a significant increase in cash received from borrowings, totaling approximately ¥131 million, compared to ¥30.5 million in the previous period[152] - The cash paid for taxes decreased to approximately ¥6.43 million from ¥8.34 million in the previous period[150] - The company’s net cash increase for the period was approximately -¥7.81 million, compared to -¥90.14 million in the previous period[152] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 75,742, with the top ten shareholders holding significant stakes[11] - The company emphasizes the importance of maintaining the legal rights of minority shareholders during the restructuring process[62] Government and Subsidies - The company received government subsidies amounting to ¥1,215,141.32 during the reporting period[8] Management and Expenses - Management expenses decreased by 34.53% compared to the same period last year, mainly due to a reduction in management costs[22] - R&D expenses decreased by 31.94% compared to the same period last year, primarily due to a reduction in R&D investment[22] - Financial expenses decreased by 82.44% compared to the same period last year, mainly due to a reduction in interest expenses[22] Future Commitments and Acquisitions - The company plans to acquire equity stakes in Anhui Weiming and Jiangsu Weiming, with the acquisition price based on evaluations by a qualified assessment agency[74] - The company has begun the process of acquiring equity in Beijing Weiming Yisheng Technology Development Co., Ltd. and will complete the necessary procedures within three months[83] - The company guarantees to prioritize any business opportunities related to pharmaceutical research and production that may compete with its operations[85] Compliance and Governance - The company has committed to maintaining its independence and compliance with relevant laws and regulations as part of its governance strategy[100] - The company will ensure compliance with relevant laws and regulations regarding related party transactions to protect the interests of minority shareholders[94]